Search

Search Constraints

You searched for: Author/Creator Singh, Sukhpreet

Search Results

1. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Issue 5 (5th July 2021)